Patient Gateway

RSS Feed

Dr Skoulidis on First-Line Divarasib Plus Pembrolizumab in KRAS G12C+ NSCLC

Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study

Clinical presentation and outcomes according to KRAS status in advanced non-small cell lung cancer

Recent Findings from Naoki Haratake and Co-Authors Yields New Data on Drug Research (M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant...

Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer

A dual-arm peptide vaccine against KRAS, EGFR, PD-L1 and VEGFR2 for non-small cell lung cancer in Vietnamese patients

KRAS-Mutant Lung Cancer: Unmet Needs Persist Beyond G12C, Expert Says

Genfleet becomes first to test oral KRAS G12D inhibitor in Phase III for NSCLC

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors

Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer